Table 4. Univariate analysis of objective response rate and disease control rate in patients harboring EGFR mutations (n = 352).
| Patient No. | ORR (%) | P value* | DCR (%) | P value* | |
|---|---|---|---|---|---|
| Age (yrs) | 0.449 | 0.880 | |||
| ≤ 65 | 189 | 56.6 | 85.2 | ||
| > 65 | 163 | 60.7 | 85.9 | ||
| Gender | 0.147 | 0.001 | |||
| Male | 131 | 53.4 | 77.1 | ||
| Female | 221 | 61.5 | 90.5 | ||
| Smoking | 0.208 | 0.013 | |||
| Non-smokers | 266 | 60.5 | 88.3 | ||
| Current/former smokers | 86 | 52.3 | 76.7 | ||
| ECOG PS # | 0.660 | <0.001 | |||
| 0–1 | 289 | 58.5 | 88.6 | ||
| ≥ 2 | 57 | 54.4 | 68.4 | ||
| Stage | 0.564 | 0.393 | |||
| IIIb | 12 | 50.0 | 75.0 | ||
| IV | 340 | 58.8 | 85.9 | ||
| Mutation types | 0.004 | 0.004 | |||
| Exon 19 deletions | 157 | 68.2 | 91.1 | ||
| Exon 21 L858R | 170 | 51.2 | 82.9 | ||
| Others | 25 | 48.0 | 68.0 | ||
| EGFR-TKIs | 0.448 | 0.142 | |||
| Gefitinib | 336 | 58.0 | 84.8 | ||
| Erlotinib | 16 | 68.8 | 100 |
EGFR, epidermal growth factor receptor; ORR, objective response rate; DCR, disease control rate; ECOG PS, ECOG PS, Eastern Cooperative Oncology Group performance status.
*Mutation types by Pearson Chi-square test; otherwise by Fisher’s exact test.
#Exclude 6 cases with missing ECOG PS data.